Aslan, Hyundai Pharm deal

Aslan granted Hyundai exclusive South Korean rights to develop and commercialize varlitinib ( ASLAN001) to treat cholangiocarcinoma (CCA). Aslan will receive an upfront payment and is eligible to receive development milestones, plus royalties. The partners plan to submit an IND by year end to the Korean Ministry of Food and Drug Safety to start clinical trials. Hyundai has first right of negotiation to develop and commercialize the product for gastric and breast cancer in the region. The partners will co-commercialize ASLAN001 in South Korea. ...